A new scalp cooling device appears to reduce chemotherapy-related alopecia in women with early-stage breast cancer, according to results of the SCALP* trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
The addition of ibandronate to adjuvant hormonal therapy provides no benefit to postmenopausal women with HR-positive breast cancer, according to early results from the phase III TEAM IIB trial (BOOG 2006-4)*.
Postmenopausal women previously treated with aromatase inhibitors (AIs) for HR-positive, HER2-negative advanced breast cancer who progressed on or after mTOR inhibitor therapy may benefit from a combination of buparlisib and fulvestrant, according to findings of the BELLE-3* study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
New drug applications approved by US FDA as of 16 - 31 May 2017 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.